![ELOCTATE® (Antihemophilic Factor Recombinant), Fc Fusion Protein]](/Content/images/eloctate-logo.svg){kind=logo}
Some see a musician. We see the nearly 70 joints behind each note
ELOCTATE Prophylaxis Offers Bleed Protection* You Can Count On.
count the reasons to choose eloctate
Up to 80% of bleeds occur in the joints.1 Good thing ELOCTATE knows a thing or two.
bleeds per year
1.6 median overall bleeds per year†
joint bleeds per year
0 median joint bleeds per year†
target joint resolved
~100% of target joints resolved in adults and adolescents treating with ELOCTATE prophylaxis‡1
PRESCRIBED
#1 prescribed extended half-life Factor VIII in the US2
Talk to your doctor to see if ELOCTATE is right for you.
* ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
† In the A-LONG study, 164 adults and adolescents ages 12-65 received ELOCTATE either every 3 to 5 days, once weekly, or on demand.
‡ The ASPIRE extension study included 150 people who completed A-LONG. Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.
1 Srivastava A, Brewer AK, Mauser- Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 013;19:e1-47.
2 #1 prescribed based on HTC reported data as of March 2022.
Get informed. Stay informed.
Let's stay in touch. We’ll occasionally send you important information on Hemophilia A and ELOCTATE. If you're new to ELOCTATE, we’ll send you a Bluetooth® speaker so you can listen to patient stories.
Resources You Can Count On
ELOCTATE provides extensive resources and support you can count on whether you’re considering a switch, just getting started, or a long-time ELOCTATE user.
product education
Step-by-step instructions to infuse and reconstitute safely and confidently.
instructions for use > reconstitution video >
experiences & expectations
Real stories from real people, helpful answers to common questions, and tools to help you talk to your doctor.
peer stories > get answers > doctor discussion guide >
financial assistance programs
Specialized programs help eligible patients with access treatment.
explore programs >
connection
Connect to local Community Relations and Education Managers and your healthcare team.
find your core > microhealth app >Contact your CoRe
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
+
IMPORTANT SAFETY INFORMATION
Do not use ELOCTATE if you have had an allergic reaction to it in the past.
Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.
Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.
Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.
If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.
These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.
INDICATIONS
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
PLEASE SEE FULL PRESCRIBING INFORMATIONMANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078
CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.
INDICATIONS
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
